PTC Therapeutics, Inc. (PTCT) Stock Forecasts

Cantor Fitzgerald raised its price target for PTC Therapeutics (NASDAQ:PTCT) to $137 from $130, citing the company's acquisition of ST-920, a gene therapy for Fabry disease. The new target suggests over 100% upside from the current stock price. PTC reported strong Q2 2026 earnings, beating expectations and raising its full-year revenue outlook. The company expects to be profitable this year with an EPS forecast of $2.00.

Cantor Fitzgerald kept its Overweight rating on PTC Therapeutics (PTCT) with a $137 price target, implying a 109.9% upside from the Sep 21 close. The firm cited PTC's acquisition of ST-920 for Fabry disease and the growing recognition of its pipeline value as reasons for the rating.

PTC THERAPEUTICS, INC. (PTCT) filed an SEC Form 8-K — Regulation FD Disclosure. Exhibit 99.1 PTC Completes Acquisition of ST-920 Fabry Disease Gene Therapy – Completion of BLA submission expected in Q4 2026 – WARREN, N.J., Sept. 21, 2026 – PTC Therapeutics, Inc., (NASDAQ: PTCT) today announced that it completed the previously announced agreement with Sangamo

PTC Therapeutics (PTCT) presented new data on its PKU therapy Sephience at the 2026 SSIEM Symposium, showing benefits in lowering phenylalanine levels and diet liberalization across a broad PKU population. The data suggest Sephience could be relevant for a wider spectrum of PKU severity. PTC raised its full-year revenue guidance to US$1.18 billion to US$1.28 billion following stronger Q2 2026 results. Analysts have varying opinions on the company's future revenue and earnings, with some predicti

PTC Therapeutics (NASDAQ: PTCT) announced new data on Sephience (sepiapterin) at the 2026 SSIEM Symposium, showing sustained metabolic control, diet liberalization, and a favorable safety profile for PKU patients. Data include significant blood Phe reductions and benefits across patient subgroups. Sephience is approved in the U.S., EU, Japan, and other regions for PKU treatment.

PTC Therapeutics (PTCT) presented data on Sephience at a metabolic disorders symposium. Clinical trials and real-world data showed significant reductions in blood phenylalanine levels and dietary liberalization in PKU patients. Sephience is approved in the U.S., EU, and Japan. The drug carries warnings about bleeding risk and hypophenylalaninemia. PKU affects about 58,000 people globally.